Cristin Rothfuss
Fortuna: 2 M $ al 31/08/2026
Fortuna: 2 M $ al 31/08/2026
Cristin L.
Rothfuss is Executive Vice President & General Counsel at Sarepta Therapeutics, Inc. since 2026.
Formerly worked as Senior Associate Director at the Office of Technology Development.
Educated at Yale University (undergraduate) and Connecticut School of Law University Of (graduate).
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 04/09/2026 | 115.519 ( 0,11 % ) | 2 M $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SAREPTA THERAPEUTICS, INC. | Consejero General | 01/02/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
Office of Technology Development
Office of Technology Development Investment ManagersFinance Office of Technology Development invests in companies located in the United States. The firm focuses on health and technology sectors. It participates in early-stage transactions. | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Office of Technology Development
Office of Technology Development Investment ManagersFinance Office of Technology Development invests in companies located in the United States. The firm focuses on health and technology sectors. It participates in early-stage transactions. | Finance |
Connecticut School of Law University Of
Connecticut School of Law University Of Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.